Especially, based on the important function of SYK in hematopoietic cells, the therapeutic action of SYK inhibitors has been confirmed in multiple myeloma, such as acute myeloid leukemia and chronic lymphocytic leukemia [1, 59, 60]. Here, SYK is linked to acute myeloid leukemia.